News Headlines

31. Samsung Biologics And Vir Biotechnology Enter Into Agreement For Large Scale Manufacture Of SARS-COV-2 Antibodies For Potential COVID-19 Treatment 4/10/2020

    Samsung Biologics and Vir Biotechnology, Inc. recently announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir’s SARS-CoV-2 monoclonal antibody (mAb) program.

32. Sharp Clinical Supports Development Of Novel COVID-19 Vaccines And Treatments 4/7/2020

    Sharp Clinical, part of UDG Healthcare and a leading provider of global clinical supply services, has confirmed that it is involved in supporting six clinical trials related to COVID-19.

33. Introducing Cytiva – Global Life Sciences Leader 4/1/2020

    Cytiva, a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics, launches today. Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and operations in 40 countries and is part of the Danaher Corporation Life Sciences platform.

34. Emergent BioSolutions Signs Agreement With Novavax To Manufacture NanoFlu™ 3/31/2020

    Emergent BioSolutions Inc. today announced an agreement with Novavax, Inc. whereby Emergent will provide molecule-to-market contract development and manufacturing (CDMO) services to produce Novavax’s NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant.

35. Ultragenyx Enters Into Strategic Partnership With Daiichi Sankyo For Gene Therapy Manufacturing Technology 3/31/2020

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a strategic partnership and non-exclusive license and technology access agreement with Daiichi Sankyo Company, Limited for Ultragenyx’s proprietary AAV-based gene therapy manufacturing technologies.

36. Cobra Biologics Is Proud To Be Part Of A Consortium To Rapidly Develop A COVID-19 Vaccine 3/31/2020

    Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, today announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19 (ChAdOx1), for fast-tracked clinical trials for COVID-19.

37. CDMO Berkshire Sterile Manufacturing To Fill Initial COVID-19 Injectables For Clinical Trials 3/24/2020

    The Berkshires, known for its rich culture and charming green mountain towns has now become a manufacturer of novel treatments and medications to aid in the ongoing pandemic.

38. Univercells Launches Cell & Gene Therapy Contract Development And Manufacturing Organization (CDMO) Exothera With GMP Capabilities In 15,000m² Site In Jumet, Belgium 3/19/2020

    Univercells has launched a contract development and manufacturing organization (CDMO), Exothera, to support cell and gene therapy developers with process development and production of viral vectors.

39. Coronavirus (COVID-19) Update: FDA Focuses On Safety Of Regulated Products While Scaling Back Domestic Inspections 3/18/2020

    Protecting the health and safety of our staff and their families is of paramount concern to the U.S. Food and Drug Administration. As a nation we must do everything we can to help slow the spread of the virus and help flatten the curve of the COVID-19 pandemic.

40. Fujifilm Diosynth Biotechnologies To Invest $83M To Expand Microbial Manufacturing Capacity 3/18/2020

    FUJIFILM Corporation announced today that it will invest approximately 9 billion yen ($83M USD) to expand the microbial production capacity of FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development & Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies.